ghadmin

September 11, 2023

Patient Choice: A Critical Piece of Shared Decision Making

Colorectal cancer (CRC) is a leading cause of cancer death in the United States. However, it is also one of the most preventable and treatable cancers if detected early through screening

September 9, 2023

The Power Within

Guardant Health Video

August 5, 2023

5 Misconceptions about CRC

Because of its widespread impact, it is important to be aware of some key facts – and misconceptions. Here are 5 common misconceptions about this cancer.

July 13, 2023

Unlocking the secrets of cancer in our blood: A founder’s perspective

A Q&A with Helmy Eltoukhy, Ph.D., co-founder, chairman and co-chief executive officer of Guardant Health

Health Equity in Clinical Trials: Patient Navigation Plays an Integral Role

Clinical trials are a critical step in developing new treatments and medications and a crucial tool for evaluating the safety and efficacy of existing treatments.

July 5, 2023

Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan

Reimbursement supports expanded access to blood-based comprehensive genomic profiling with Guardant360 CDx for patients with advanced solid tumor cancers and their care teams across Japan

June 21, 2023

Can a Blood Test Screen for Colon Cancer? Guardant Health Chief Medical Officer Shares Promising Update

Currently, there’s a huge push in the cancer community to develop blood tests that can screen for different types of the disease. A company called Guardant Health is working on one of these tools, a test called “Shield” that can screen blood for signs of early-stage colon cancer.

June 19, 2023

EUCOPE launches the European Coalition for Access to Comprehensive Genomic Profiling (ECGP)

EUCOPE, along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP)

May 31, 2023

Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance

May 17, 2023

Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling

With new coverage from Anthem Blue Cross and Blue Shield, Aetna and Humana, Guardant360 CDx/Guardant360 liquid biopsy test now covered by all major commercial health insurers